Welcome to our dedicated page for Adial Pharmaceuticals news (Ticker: ADIL), a resource for investors and traders seeking the latest updates and insights on Adial Pharmaceuticals stock.
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addictions and related disorders. News about Adial often centers on the progress of its lead investigational drug, AD04, a genetically targeted serotonin-3 receptor antagonist being developed for Alcohol Use Disorder (AUD) in heavy drinking patients with specific genotypes.
On this page, readers can find coverage of Adial’s clinical development milestones, including updates on the ONWARD™ pivotal Phase 3 trial and preparations for a new Phase 3 adaptive program informed by End of Phase 2 (EOP2) feedback from the U.S. Food and Drug Administration (FDA). Company announcements describe FDA recognition of AUD as an unmet need, support for Adial’s adaptive trial design, and confirmation of primary efficacy endpoints based on heavy drinking days.
Adial’s news flow also highlights its precision medicine strategy. Releases describe a partnership with Genomind to validate a cheek swab genetic test that identifies SNPs in serotonergic system genes such as HTR3A, HTR3B, and SLC6A4, enabling selection of biomarker-positive patients, including those with the AG+ genotype. Additional stories cover intellectual property developments, such as provisional and international patent applications for AD04 that the company expects, once granted, to protect core assets to at least 2045.
Investors and observers can also follow capital markets and listing-related updates, including public offerings of stock and warrants, at-the-market sales agreements, Nasdaq compliance notices, and extensions related to minimum bid price requirements. Together, these items provide context on how Adial is financing and structuring its efforts to advance AD04 and its broader addiction treatment pipeline. Bookmark this page to review new regulatory, clinical, financing, and intellectual property announcements as they are reported.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) announced a business update for the fiscal year 2022, concluding with $4.0 million in cash and cash equivalents. Key highlights include the pivotal ONWARD™ Phase 3 trial's positive results for AD04 in reducing heavy drinking days among patients with Alcohol Use Disorder. The company is pursuing regulatory approvals, having secured meetings with the U.S. FDA and European agencies. Adial also closed a $0.75 million share offering and engaged The Keswick Group to enhance partnership activities. The company reported a reduced net loss of $12.7 million for the year, down from $19.4 million in 2021.
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) announced the engagement of The Keswick Group, LLC, led by Tony Goodman, to enhance its partnering efforts. This strategic move follows recent analysis of the ONWARD™ data, which highlighted significant results for the AD04 treatment in reducing heavy drinking days among specific genotypes. With promising outcomes from the Phase 3 clinical trial, Adial aims to secure strategic partnerships to expedite AD04's market entry, targeting both the U.S. and European regulatory environments. The company focuses on addiction therapies, with AD04 also positioned for potential treatment of opioid use disorder and other addictions.
Adial Pharmaceuticals, based in Charlottesville, Va., announces that Cary Claiborne, CEO, will present at the 35th Annual Roth Conference on March 14, 2023. The event takes place at The Ritz Carlton, Laguna Niguel in Dana Point, California, and Claiborne's presentation is scheduled for 12:00 PM PT. Investors can access a live audio webcast of the presentation via this link. Adial focuses on developing therapies for addiction; its lead drug AD04 targets Alcohol Use Disorder with promising results from its Phase 3 trial.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) has announced a strategic update regarding its lead compound, AD04, for Alcohol Use Disorder (AUD). A Type C meeting with the FDA is confirmed for Q2 2023, alongside planned discussions with five European regulatory authorities. Recent analysis of ONWARD™ data has identified specific genotypes with promising responses to AD04, and market research indicates potential unit pricing could exceed previous estimates. The company aims to engage partners for U.S. and European commercialization, highlighting a significant market opportunity for AUD treatment.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) is set to host a conference call and webcast on March 7, 2023, at 8:15 a.m. ET, to discuss updates on its regulatory and partnering strategies in the United States and Europe. The call will also cover findings from a subgroup analysis of ONWARD data related to its lead investigational drug, AD04, aimed at treating Alcohol Use Disorder (AUD). During the ONWARD Phase 3 trial, AD04 showed promising results in reducing heavy drinking among targeted genotype patients. The event is accessible via a live webcast and telephone for wider participation.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) announced on February 24, 2023, that it will conduct a $0.75 million registered direct offering of common stock. The purchase price is set at $0.41 per share, totaling 1,829,269 shares to be sold. The offering is arranged through Joseph Gunnar & Co., LLC as the placement agent and is expected to close on February 24, 2023, pending customary conditions. The offering is registered under an effective Form S-3 registration statement with the SEC, and a prospectus supplement will be filed to provide further details.
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) announced plans for significant regulatory meetings in 2023, including a Type C meeting with the FDA in the second quarter. These discussions aim to advance clinical development for AD04, targeting alcohol use disorder (AUD). The company is also engaging with five European regulatory authorities, seeking guidance toward expedited approvals. CEO Cary Claiborne emphasized these meetings as crucial for completing AD04's development and exploring potential partnerships for funding and market strategies. The ONWARD™ Phase 3 trial showed promising results for AD04, potentially expanding its use to other addictions.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) announced a strategic focus on the late-stage development of AD04 for Alcohol Use Disorder (AUD) while potentially selling its subsidiary, Purnovate, to a new entity led by former CEO William Stilley. This option agreement allows Adenomed to purchase Purnovate's assets for $450,000, with Adial eligible for up to $83 million in milestones and royalties. The deal aims to reduce Adial's burn rate and extend its cash runway. Stilley plans to maximize Purnovate's drug candidates' value, emphasizing the potential of adenosine technology in unmet medical needs.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) is advancing its regulatory strategy for AD04, following promising Phase 3 ONWARD™ trial results for treating Alcohol Use Disorder (AUD). The company aims for commercialization in Europe and North America, positively impacting millions with AUD. Adial also reported financial results for Q3 2022, with a reduced net loss of $3.1 million ($0.12/share), down from $4.3 million in Q3 2021. Additionally, R&D expenses decreased by 26% to $1.3 million, while general and administrative costs fell by 18% to $1.9 million, highlighting improved cost management.
Adial Pharmaceuticals announced positive results for PNV-5030, a treatment for chronic pain, demonstrating significant pain reduction in animal models. In a study involving rats, PNV-5030 reduced pain by up to 76% compared to placebo and showed higher efficacy than acetaminophen. The drug exhibited over 1000-fold selectivity over the A1 receptor and improved solubility by more than 50 times compared to similar compounds. This breakthrough could lead to advancements toward human clinical trials, enhancing Adial's drug development pipeline.